AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients.
A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …